Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL Meeting Abstract


Authors: Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
Abstract Title: Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL
Meeting Title: 58th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 128
Issue: 22
Meeting Dates: 2016 Dec 3-6
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2016-12-02
Language: English
ACCESSION: WOS:000394446805063
PROVIDER: wos
Notes: Meeting Abstract: 58 -- Source: Wos
MSK Authors
  1. Renier J Brentjens
    187 Brentjens
  2. Jae Hong Park
    127 Park
  3. Michel W J Sadelain
    449 Sadelain
  4. Isabelle C Riviere
    158 Riviere
  5. Xiuyan Wang
    61 Wang
  6. Terence John Purdon
    32 Purdon
  7. Mark Blaine Geyer
    11 Geyer
Related MSK Work